CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer
Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e014668
DOI: 10.1136/jitc-2025-014668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.05.2026. Verfasst von Mariana Carreira und 8 weiteren Autor:innen. Beteiligte Einrichtung: GIMM, Lisbon, Portugal. Hauptthemen laut MEDLINE: Receptors, CXCR3, Colorectal Neoplasms, Receptors, Antigen, T-Cell, gamma-delta, Intraepithelial Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, Takeda Development Center Americas, Inc, Liga Portuguesa Contra o Cancro.
Abstract (Originalsprache)
Immunotherapy has transformed cancer treatment, yet its efficacy in solid tumors, and particularly in colorectal cancer (CRC), remains limited by insufficient infiltration of endogenous or adoptively transferred immune cells. Our group developed Delta One T (DOT) cells, an allogeneic Vδ1-enriched γδ T-cell product with demonstrated efficacy in CRC models, but the critical mechanisms guiding their tumor homing are unclear. Here we show that DOT cells acquire a specific chemokine receptor profile during expansion to support tumor infiltration, characterized by prominent CXCR3 expression. Importantly, CXCR3 ligands (CXCL9–11) are expressed by CRC cell lines and primary tumors, and correlate with Vδ1 T cell infiltration and DOT-cell recruitment. CXCR3 signaling is critical for DOT-cell migration in vitro and in vivo, as pharmacologic blockade reduced tumor homing, whereas enhancing CXCR3 ligand expression increased DOT-cell infiltration and improved tumor control. These findings establish CXCR3 signaling as a key regulator of DOT-cell trafficking and a prime target to boost γδ T cell-based immunotherapies for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GIMM, Lisbon, Portugal.
- Hospital de Santa Maria, Lisbon, Portugal.
- Universidade de Lisboa, Lisboa, Portugal bssantos@medicina.ulisboa.pt rafael.blanco@gimm.pt.
- GIMM, Lisbon, Portugal bssantos@medicina.ulisboa.pt rafael.blanco@gimm.pt.
Förderung
- Fundação para a Ciência e a Tecnologia
- Takeda Development Center Americas, Inc
- Liga Portuguesa Contra o Cancro
Zitieren
APA
Carreira, M., Barros, L., Cruz, R. M., Ferreira, C., Costa, C., Ferreira, C. M., Mensurado, S., Silva-Santos, B., & Blanco-Domínguez, R. (2026). CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer. Journal for ImmunoTherapy of Cancer, 14(5), e014668. https://doi.org/10.1136/jitc-2025-014668
Vancouver
Carreira M, Barros L, Cruz RM, Ferreira C, Costa C, Ferreira CM, et al. CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer. Journal for ImmunoTherapy of Cancer. 2026;14(5):e014668. doi:10.1136/jitc-2025-014668
BibTeX
@article{Carreira2026,
author = {Carreira, Mariana and Barros, Leandro and Cruz, Rafael M and Ferreira, Cristina and Costa, Carla and Ferreira, Carlos M and Mensurado, Sofia and Silva-Santos, Bruno and Blanco-Domínguez, Rafael},
title = {CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {5},
pages = {e014668},
doi = {10.1136/jitc-2025-014668}
}
EUVIMED